Corcept Therapeutics (NASDAQ: CORT) reported Q4 EPS of $0.28, $0.01 better than the analyst estimate of $0.27. Revenue for the quarter came in at $135.4 million versus the consensus estimate of $130.31 million.

For earnings history and earnings-related data on Corcept Therapeutics (CORT) click here.